The gut microbiome-immune-antioxidant axis: Redox-driven host-microbial crosstalk as a determinant of cancer immunotherapy response
Eurasian Journal of Medicine and Oncology · 15.09.2026 · 10 (5) · 026240265
DOI: 10.36922/ejmo026240265 ↗Kurz gefasst
Fachartikel in der Zeitschrift Eurasian Journal of Medicine and Oncology, online erschienen am 15.09.2026. Verfasst von Muhammad Alaa Eldeen und 9 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
The gut microbiome, host redox homeostasis, and immune regulation are mechanistically interdependent. However, their integrated role in driving resistance to immune checkpoint inhibitors remains incompletely defined.
Objective
This review introduces the gut microbiome, immune, and antioxidant (GIA) axis as a unifying, systems-level conceptual framework to explain treatment heterogeneity and optimize cancer immunotherapy outcomes.Scope: We synthesize current mechanistic and translational evidence linking microbiota-derived metabolites, including short-chain fatty acids, bile acids, and tryptophan derivatives, to oxidative stress responses, mitochondrial fitness, and anti-tumor immune competence across colorectal, hepatobiliary, and neuro-oncologic malignancies.Key findings: Disruption of the GIA network promotes immunotherapy resistance through excessive oxidative burden, pathological Nrf2 signaling, and the expansion of immunosuppressive myeloid populations. Conversely, targeted microbiome interventions, including probiotics, postbiotics, and fecal microbiota transplantation, can successfully restore redox-immune equilibrium, remodel the tumor microenvironment, and enhance the efficacy of checkpoint blockade.
Conclusion
We propose a precision immuno-oncology framework utilizing composite GIA-axis biomarker profiling for patient stratification. Integrating these multidisciplinary insights identifies actionable translational opportunities to overcome therapeutic resistance and transition host-microbiome-immune integration from conceptual promise to clinical reality.
Zitieren
APA
Eldeen, M. A., Choi, J., Kim, H. J., Park, S., Rani, A., Akl, M. A., Youssef, M. E., Khodear, G. A. M., Abdelraheem, K. M., & Kim, B. (2026). The gut microbiome-immune-antioxidant axis: Redox-driven host-microbial crosstalk as a determinant of cancer immunotherapy response. Eurasian Journal of Medicine and Oncology, 10(5), 026240265. https://doi.org/10.36922/ejmo026240265
Vancouver
Eldeen MA, Choi J, Kim HJ, Park S, Rani A, Akl MA, et al. The gut microbiome-immune-antioxidant axis: Redox-driven host-microbial crosstalk as a determinant of cancer immunotherapy response. Eurasian Journal of Medicine and Oncology. 2026;10(5):026240265. doi:10.36922/ejmo026240265
BibTeX
@article{Eldeen2026,
author = {Eldeen, Muhammad Alaa and Choi, Jinwon and Kim, Hyo Jeong and Park, Sohyun and Rani, Amama and Akl, Mohamed A. and Youssef, Mohamed E. and Khodear, Gehan A. M. and Abdelraheem, Kareem M. and Kim, Bonglee},
title = {The gut microbiome-immune-antioxidant axis: Redox-driven host-microbial crosstalk as a determinant of cancer immunotherapy response},
journal = {Eurasian Journal of Medicine and Oncology},
year = {2026},
volume = {10},
number = {5},
pages = {026240265},
doi = {10.36922/ejmo026240265}
}
EUVIMED